 Humanigen Inc. NASDAQ: HGEN share rallied Monday amid positive Phase 3 data demonstrating Lenzilumab TM achieved its primary endpoint. The drug improves survival without the need for mechanical ventilation in hospitalized COVID-19 patients. 